Search research articles
Contact Us
Filters
Showing results (11-20 of 57) with videos related to
Page
of 6
Sort By:
Breast Cancer Research and Treatment
|
November 5, 2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Frontiers in Pharmacology
|
December 27, 2021
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
Michele Fusaroli, Emanuel Raschi, Milo Gatti, et al.
Drug Safety
|
September 24, 2025
Charting and Sidestepping the Pitfalls of Disproportionality Analysis
Michele Fusaroli, Daniele Sartori, Eugène P van Puijenbroek, et al.
Journal for Immunotherapy of Cancer
|
November 3, 2024
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
Roberta Noseda, Francesca Bedussi, Valentina Giunchi, et al.
Addiction (Abingdon, England)
|
November 12, 2022
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic construct
Michele Fusaroli, Luca Pellegrini, Riccardo Fusaroli, et al.
Cancers
|
January 8, 2023
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase<sup>®</sup> Spontaneous Reporting System
Roberta Noseda, Laura Müller, Francesca Bedussi, et al.
Journal of Clinical Psychopharmacology
|
June 20, 2024
Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports: A Note of Caution
Michele Fusaroli, Charles Khouri, Elisabetta Poluzzi, et al.
Journal of Nephrology
|
November 11, 2021
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
Milo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Drug Safety
|
March 21, 2026
International Medicinal Product Information Documents: A Quantitative Content Analysis of Instructions for Preventing, Mitigating, and Monitoring Adverse Drug Reactions
Daniele Sartori, Michele Fusaroli, Jeffrey K Aronson, et al.
Expert Opinion on Drug Safety
|
July 19, 2021
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system
Milo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 57) with videos related to
Sort By:
Page
of 6
Breast Cancer Research and Treatment
|
November 5, 2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Frontiers in Pharmacology
|
December 27, 2021
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
Michele Fusaroli, Emanuel Raschi, Milo Gatti, et al.
Drug Safety
|
September 24, 2025
Charting and Sidestepping the Pitfalls of Disproportionality Analysis
Michele Fusaroli, Daniele Sartori, Eugène P van Puijenbroek, et al.
Journal for Immunotherapy of Cancer
|
November 3, 2024
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
Roberta Noseda, Francesca Bedussi, Valentina Giunchi, et al.
Addiction (Abingdon, England)
|
November 12, 2022
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic construct
Michele Fusaroli, Luca Pellegrini, Riccardo Fusaroli, et al.
Cancers
|
January 8, 2023
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase<sup>®</sup> Spontaneous Reporting System
Roberta Noseda, Laura Müller, Francesca Bedussi, et al.
Journal of Clinical Psychopharmacology
|
June 20, 2024
Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports: A Note of Caution
Michele Fusaroli, Charles Khouri, Elisabetta Poluzzi, et al.
Journal of Nephrology
|
November 11, 2021
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
Milo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Drug Safety
|
March 21, 2026
International Medicinal Product Information Documents: A Quantitative Content Analysis of Instructions for Preventing, Mitigating, and Monitoring Adverse Drug Reactions
Daniele Sartori, Michele Fusaroli, Jeffrey K Aronson, et al.
Expert Opinion on Drug Safety
|
July 19, 2021
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system
Milo Gatti, Michele Fusaroli, Emanuel Raschi, et al.
Page
of 6